The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing BCMA- & GPRC5D- targeted therapies outside specialist centers: unmet educational needs
Elena Zamagni, MD, PhD, University of Bologna, Bologna, Italy, emphasizes the need to educate community hematologists on managing and preventing toxicity associated with BCMA- and GPRC5D-targeted therapies in multiple myeloma treatment to ensure safe use in non-academic and community centers. Dr Zamagni highlights the need for a roadmap and educational activities at the local level to support the successful implementation of these therapies. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Thank you. Yes, I think this is something of utmost importance because it’s quite a burden of management to correctly follow up and prevent toxicity. We had a wonderful session here in Glasgow regarding prevention of toxicity and management of the toxicity. So I think that it is so important to use bispecific, bela, CAR T-cells in real life. So for those who are not so experienced and don’t have so many patients, I think now there is quite a good roadmap, a list of things to be put in place and to be done before and during treatment...
Thank you. Yes, I think this is something of utmost importance because it’s quite a burden of management to correctly follow up and prevent toxicity. We had a wonderful session here in Glasgow regarding prevention of toxicity and management of the toxicity. So I think that it is so important to use bispecific, bela, CAR T-cells in real life. So for those who are not so experienced and don’t have so many patients, I think now there is quite a good roadmap, a list of things to be put in place and to be done before and during treatment. So I think that at the regional level, it’s very important to provide to all the smallest centers what you have to do. It’s quite simple because it’s quite logical and quite established, but for sure you have to share with your colleagues. Otherwise, they may get lost in the management because the treatments are very effective but the burden of the management is a little higher as compared to what is happening with the standard of care treatment, in particular I’m referring, of course, to infection prevention, but not only. So it’s good, to my opinion, to have educational activities on the territory at the local level to make all the people able to put in place these treatments.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
